Statins are associated with low risk of venous thromboembolism in patients with cancer: A prospective and observational cohort study

Thrombosis Research

Volumn 134, Issue 5, 2014, Pages 1008-1013

  Lötsch, Felix ^a   Königsbrügge, Oliver ^a   Posch, Florian ^a   Zielinski, Christoph ^a   Pabinger, Ingrid ^a   Ay, Cihan ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Neoplasms; Simvastatin; Statins; Thrombosis; Venous thromboembolism

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; ATORVASTATIN; CLOPIDOGREL; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN;

ADULT; AGED; ARTICLE; BRAIN CANCER; BREAST CANCER; CANCER PATIENT; CANCER REGRESSION; CARDIOVASCULAR RISK; CEREBRAL SINUS THROMBOSIS; COHORT ANALYSIS; COLON CANCER; DEEP VEIN THROMBOSIS; DISEASE COURSE; DRUG USE; FEMALE; FOLLOW UP; HUMAN; INFERIOR CAVA VEIN; JUGULAR VEIN; KIDNEY CANCER; LOW DRUG DOSE; LOW RISK PATIENT; LUNG CANCER; LUNG EMBOLISM; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; NEOPLASM; OBSERVATIONAL STUDY; PANCREAS CANCER; PORTAL VEIN THROMBOSIS; PRESCRIPTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTATE CANCER; RISK ASSESSMENT; RISK REDUCTION; STOMACH CANCER; VENOUS THROMBOEMBOLISM; COMPLICATION; MIDDLE AGED; RISK FACTOR;

AGED; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; NEOPLASMS; RISK ASSESSMENT; RISK FACTORS; SIMVASTATIN; VENOUS THROMBOEMBOLISM;

EID: 84927673214     PISSN: 00493848     EISSN: 18792472     Source Type: Journal    
DOI: 10.1016/j.thromres.2014.09.001     Document Type: Article

References (45)

1. Trousseau A. Phlegmasia alba dolens. Cln Med Hotel Dieu de Paris 1865; 3:94-6.
2. Zangari M, Anaissie E, Barlogie B., Badros A, Desikan R, Gopal A.V., et al. Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy. Blood 2001; 98:1614-5.
3. Khorana AA, Connolly GC. Assessing risk of venous thromboembolism in the patient with cancer. J Clin Oncol 2009; 27:4839-47.
4. Sousou T, Khorana A. Identifying cancer patients at risk for venous thromboembo-lism. Hamostaseologie 2009; 29:121-4.
5. Heit JA, Silverstein MD, Mohr D.N., Petterson TM, O'Fallon WM, Melton 3rd LJ. Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study. Arch Intern Med 2000; 160:809-15.
6. Khorana AA, Kuderer NM, Culakova E, Lyman G.H., Francis CW. Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood 2008; 111:4902-7.
7. Ay C, Dunkler D, Marosi C., Chiriac AL, Vormittag R, Simanek R, et al. Prediction of venous thromboembolism in cancer patients. Blood 2010; 116:5377-82.
8. Thaler J, Ay C, Pabinger I. Venous thromboembolism in cancer patients - risk scores and recent randomised controlled trials. Thromb Haemost 2012; 108:1042-8.
9. Herrington DM, Vittinghoff E, Lin F., Fong J, Harris F, Hunninghake D., et al. Statin therapy, cardiovascular events, and total mortality in the Heart and Estrogen/Progestin Replacement Study (HERS). Circulation 2002; 105:2962-7.
10. Glynn RJ, Danielson E, Fonseca F.A., Genest J., Gotto Jr AM, Kastelein JJ, et al. A randomized trial of rosuvastatin in the prevention of venous thromboembolism. N Engl J Med 2009; 360:1851-61.
11. Agarwal V, Phung OJ, Tongbram V, Bhardwaj A., Coleman CI. Statin use and the prevention of venous thromboembolism: a meta-analysis. Int J Clin Pract 2010; 64: 1375-83.
12. Squizzato A, Galli M, Romualdi E., Dentali F, Kamphuisen PW, Guasti L, et al. Statins, fibrates, and venous thromboembolism: a meta-analysis. Eur Heart J 2010; 31: 1248-56.
13. Pai M, Evans NS, Shah S.J., Green D., Cook D, Crowther MA. Statins in the prevention of venous thromboembolism: a meta-analysis of observational studies. Thromb Res 2011; 128:422-30.
14. Rahimi K, Bhala N, Kamphuisen P., Emberson J, Biere-Rafi S, Krane V, et al. Effect of statins on venous thromboembolic events: a meta-analysis of published and unpublished evidence from randomised controlled trials. PLoS Med 2012; 9:e1001310.
15. Khemasuwan D, Divietro ML, Tangdhanakanond K, Pomerantz S.C., Eiger G. Statins decrease the occurrence of venous thromboembolism in patients with cancer. Am J Med 2010; 123:60-5.
16. Ridker PM, Danielson E, Fonseca F.A., Genest J., Gotto Jr AM, Kastelein JJ, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008; 359:2195-207.
17. Llevadot J, Murasawa S, Kureishi Y., Uchida S, Masuda H, Kawamoto A., et al. HMG-CoA reductase inhibitor mobilizes bone marrow-derived endothelial progenitor cells. J Clin Invest 2001; 108:399-405.
18. Huhle G, Abletshauser C, Mayer N., Weidinger G, Harenberg J, Heene DL. Reduction of platelet activity markers in type II hypercholesterolemic patients by a HMG-CoA-re-ductase inhibitor. Thromb Res 1999; 95:229-34.
19. Koh KK. Effects of statins on vascular wall: vasomotor function, inflammation, and plaque stability. Cardiovasc Res 2000; 47:648-57.
20. Violi F, Calvieri C, Ferro D., Pignatelli P. Statins as antithrombotic drugs. Circulation 2013; 127:251-7.
21. Eto M, Kozai T, Cosentino F., Joch H, Luscher TF. Statin prevents tissue factor expression in human endothelial cells: role of Rho/Rho-kinase and Akt pathways. Circulation 2002; 105:1756-9.
22. Holschermann H, Schuster D, Parviz B., Haberbosch W, Tillmanns H, Muth H. Statins prevent NF-kappaB transactivation independently of the IKK-pathway inhuman en-dothelial cells. Atherosclerosis 2006; 185:240-5.
23. Undas A, Brummel-Ziedins KE, Mann KG. Statins and blood coagulation. Arterioscler Thromb Vasc Biol 2005; 25:287-94.
24. Liao JK, Laufs U. Pleiotropic effects of statins. Annu Rev Pharmacol Toxicol 2005; 45: 89-118.
25. Ay C, Simanek R, Vormittag R., Dunkler D, Alguel G, Koder S., et al. High plasma levels of soluble P-selectin are predictive of venous thromboembolism in cancer patients: results from the Vienna Cancer and Thrombosis Study (CATS). Blood 2008; 112:2703-8.
26. Ay C, Vormittag R, Dunkler D., Simanek R, Chiriac AL, Drach J, et al. D-dimer and pro-thrombin fragment1 + 2 predict venous thromboembolism inpatients with cancer: results from the Vienna Cancer and Thrombosis Study. J Clin Oncol 2009; 27:4124-9.
27. Vormittag R, Simanek R, Ay C., Dunkler D, Quehenberger P, Marosi C., et al. High factor VIII levels independently predict venous thromboembolism in cancer patients: the cancer and thrombosis study. Arterioscler Thromb Vasc Biol 2009; 29:2176-81.
28. Kanz R, Vukovich T, Vormittag R., Dunkler D, Ay C, Thaler J., et al. Thrombosis risk and survival in cancer patients with elevated C-reactive protein. J Thromb Haemost 2011; 9:57-63.
29. Gray R.A Class of K-Sample Tests for Comparing the Cumulative Incidence of a Competing Risk. Ann Stat 1988; 16:1141-54.
30. Fine JP, Gray RJ. A Proportional Hazards Model for the Subdistribution of a Competing Risk. J Am Stat Assoc 1999; 94:496-509.
31. Austin PC. A Tutorial and Case Study in Propensity Score Analysis: An Application to Estimating the Effect of In-Hospital Smoking Cessation Counseling on Mortality. Multivar Behav Res 2011; 46:119-51.
32. Baigent C, Keech A, Kearney P.M., Blackwell L., Buck G, Pollicino C, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005; 366:1267-78.
33. Prandoni P, Lensing AW, Piccioli A, Bernardi E., Simioni P, Girolami B, et al. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood 2002; 100:3484-8.
34. Nielsen SF, Nordestgaard BG, Bojesen SE. Statin use and reduced cancer-related mortality. N Engl J Med 2012; 367:1792-802.
35. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med 2005; 353:487-97.
36. Benner JS, Glynn RJ, Mogun H, Neumann P.J., Weinstein MC, Avorn J. Long-term persistence in use of statin therapy in elderly patients. JAMA 2002; 288:455-61.
37. Becattini C, Agnelli G, Schenone A., Eichinger S, Bucherini E, Silingardi M., et al. Aspirin for preventing the recurrence of venous thromboembolism. N Engl J Med 2012; 366: 1959-67.
38. Brighton TA, Eikelboom JW, Mann K, Mister R., Gallus A, Ockelford P, et al. Low-dose aspirin for preventing recurrent venous thromboembolism. N Engl J Med 2012; 367: 1979-87.
39. Adams NB, Lutsey PL, Folsom A.R., Herrington DH, Sibley CT, Zakai NA, et al. Statin therapy and levels of hemostatic factors in a healthy population: the Multi-Ethnic Study of Atherosclerosis. J Thromb Haemost 2013; 11:1078-84.
40. Coussens LM, Werb Z. Inflammation and cancer. Nature 2002; 420:860-7.
41. Falanga A. Thrombophilia in cancer. Semin Thromb Hemost 2005; 31:104-10.
42. Khorana AA, Francis CW, Culakova E, Kuderer N.M., Lyman GH. Frequency, risk factors, and trends for venous thromboembolism among hospitalized cancer patients. Cancer 2007; 110:2339-46.
43. Kroger K, Weiland D, Ose C., Neumann N, Weiss S, Hirsch C., et al. Risk factors for venous thromboembolic events in cancer patients. Ann Oncol 2006; 17:297-303.
44. Khemasuwan D, Chae YK, Gupta S, Carpio A., Yun JH, Neagu S, et al. Dose-related effect of statins in venous thrombosis risk reduction. Am J Med 2011; 124:852-9.
45. Shrank WH, Patrick AR, Brookhart MA. Healthy user and related biases in observational studies of preventive interventions: a primer for physicians. J Gen Intern Med 2011; 26:546-50.